Myeloperoxidase: a Potential Therapeutic Target for Coronary Artery Disease

Overview

Journal Expert Opin Ther Targets

Publisher Informa Healthcare

Specialty Pharmacology

Date 2020 Apr 28

PMID 32336171

Citations 14

Authors

Thanat Chaikijurajai

W H Wilson Tang

Affiliations

Soon will be listed here.

Abstract

Introduction: Coronary artery disease (CAD) poses significant morbidity and mortality globally. Despite significant advances in treatment interventions, residual cardiovascular risks remain unchecked. Recent clinical trials have shed light on the potential therapeutic benefits of targeting anti-inflammatory pathways. Myeloperoxidase (MPO) plays an important role in atherosclerotic plaque formation and destabilization of the fibrous cap; both increase the risk of atherosclerotic cardiovascular disease and especially CAD.

Areas Covered: This article examines the role of MPO in the pathogenesis of atherosclerotic CAD and the mechanistic data from several key therapeutic drug targets. There have been numerous interesting studies on prototype compounds that directly or indirectly attenuate the enzymatic activities of MPO, and subsequently exhibit atheroprotective effects; these include aminobenzoic acid hydrazide, ferulic acid derivative (INV-315), thiouracil derivatives (PF-1355 and PF-06282999), 2-thioxanthines derivative (AZM198), triazolopyrimidines, acetaminophen, N-acetyl lysyltyrosylcysteine (KYC), flavonoids, and alternative substrates such as thiocyanate and nitroxide radical.

Expert Opinion: Future investigations must determine if the cardiovascular benefits of direct systemic inhibition of MPO outweigh the risk of immune dysfunction, which may be less likely to arise with alternative substrates or MPO inhibitors that selectively attenuate atherogenic effects of MPO.

Citing Articles

Relationship Between Serum Levels of Oxidized Lipoproteins, Circulating Levels of Myeloperoxidase and Paraoxonase 1, and Diet in Young Subjects with Insulin Resistance.

Marchan-Figueroa Y, Tepec-Casarrubias B, De la Cruz-Mosso U, Astudillo-Lopez C, Matia-Garcia I, Salgado-Goytia L Nutrients. 2024; 16(22).

PMID: 39599716 PMC: 11597308. DOI: 10.3390/nu16223930.

Development and validation of a nomogram to predict severe influenza.

Zhao M, Zhang B, Yan M, Zhao Z Immun Inflamm Dis. 2024; 12(9):e70026.

PMID: 39340342 PMC: 11437489. DOI: 10.1002/iid3.70026.

(Chemical) Roles of HOCl in Rheumatic Diseases.

Leopold J, Schiller J Antioxidants (Basel). 2024; 13(8).

PMID: 39199167 PMC: 11351306. DOI: 10.3390/antiox13080921.

RNAseq of INOCA patients identifies innate, invariant, and acquired immune changes: potential autoimmune microvascular dysfunction.

Jaatinen K, Shah P, Mazhari R, Hayden Z, Wargowsky R, Jepson T Front Cardiovasc Med. 2024; 11:1385457.

PMID: 38978787 PMC: 11228317. DOI: 10.3389/fcvm.2024.1385457.

Nitrite Attenuates the In Vitro Inflammatory Response of Immune Cells to the SARS-CoV-2 S Protein without Interfering in the Antioxidant Enzyme Activation.

Ferrer M, Reynes C, Jimenez L, Malagraba G, Monserrat-Mesquida M, Bouzas C Int J Mol Sci. 2024; 25(5).

PMID: 38474248 PMC: 10932026. DOI: 10.3390/ijms25053001.

References

Kapiotis S, Sengoelge G, Hermann M, Held I, Seelos C, Gmeiner B . Paracetamol catalyzes myeloperoxidase-initiated lipid oxidation in LDL. Arterioscler Thromb Vasc Biol. 1997; 17(11):2855-60. DOI: 10.1161/01.atv.17.11.2855. View

Bennett M, Sinha S, Owens G . Vascular Smooth Muscle Cells in Atherosclerosis. Circ Res. 2016; 118(4):692-702. PMC: 4762053. DOI: 10.1161/CIRCRESAHA.115.306361. View

Tiyerili V, Camara B, Becher M, Schrickel J, Lutjohann D, Mollenhauer M . Neutrophil-derived myeloperoxidase promotes atherogenesis and neointima formation in mice. Int J Cardiol. 2015; 204:29-36. DOI: 10.1016/j.ijcard.2015.11.128. View

Aratani Y . Myeloperoxidase: Its role for host defense, inflammation, and neutrophil function. Arch Biochem Biophys. 2018; 640:47-52. DOI: 10.1016/j.abb.2018.01.004. View

Smith J . Myeloperoxidase, inflammation, and dysfunctional high-density lipoprotein. J Clin Lipidol. 2010; 4(5):382-8. PMC: 2976566. DOI: 10.1016/j.jacl.2010.08.007. View

Kato Y, Nagao A, Terao J, Osawa T . Inhibition of myeloperoxidase-catalyzed tyrosylation by phenolic antioxidants in vitro. Biosci Biotechnol Biochem. 2003; 67(5):1136-9. DOI: 10.1271/bbb.67.1136. View

Tiden A, Sjogren T, Svensson M, Bernlind A, Senthilmohan R, Auchere F . 2-thioxanthines are mechanism-based inactivators of myeloperoxidase that block oxidative stress during inflammation. J Biol Chem. 2011; 286(43):37578-89. PMC: 3199503. DOI: 10.1074/jbc.M111.266981. View

Kumar A, Piedrafita F, Reynolds W . Peroxisome proliferator-activated receptor gamma ligands regulate myeloperoxidase expression in macrophages by an estrogen-dependent mechanism involving the -463GA promoter polymorphism. J Biol Chem. 2003; 279(9):8300-15. DOI: 10.1074/jbc.M311625200. View

Sugiyama S, Okada Y, Sukhova G, Virmani R, Heinecke J, Libby P . Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol. 2001; 158(3):879-91. PMC: 1850342. DOI: 10.1016/S0002-9440(10)64036-9. View

10.

Hazen S, Heinecke J . 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J Clin Invest. 1997; 99(9):2075-81. PMC: 508036. DOI: 10.1172/JCI119379. View

11.

Hazell L, van den Berg J, Stocker R . Oxidation of low-density lipoprotein by hypochlorite causes aggregation that is mediated by modification of lysine residues rather than lipid oxidation. Biochem J. 1994; 302 ( Pt 1):297-304. PMC: 1137223. DOI: 10.1042/bj3020297. View

12.

Bjornsdottir H, Welin A, Michaelsson E, Osla V, Berg S, Christenson K . Neutrophil NET formation is regulated from the inside by myeloperoxidase-processed reactive oxygen species. Free Radic Biol Med. 2015; 89:1024-35. DOI: 10.1016/j.freeradbiomed.2015.10.398. View

13.

Nenseter M, Halvorsen B, Rosvold O, Rustan A, Drevon C . Paracetamol inhibits copper ion-induced, azo compound-initiated, and mononuclear cell-mediated oxidative modification of LDL. Arterioscler Thromb Vasc Biol. 1995; 15(9):1338-44. DOI: 10.1161/01.atv.15.9.1338. View

14.

Podrez E, Febbraio M, Sheibani N, Schmitt D, Silverstein R, Hajjar D . Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species. J Clin Invest. 2000; 105(8):1095-108. PMC: 300829. DOI: 10.1172/JCI8574. View

15.

Lee E, Hirouchi M, Hosokawa M, SAYO H, Kohno M, Kariya K . Inactivation of peroxidases of rat bone marrow by repeated administration of propylthiouracil is accompanied by a change in the heme structure. Biochem Pharmacol. 1988; 37(11):2151-3. DOI: 10.1016/0006-2952(88)90574-6. View

16.

Asselbergs F, Reynolds W, Cohen-Tervaert J, Jessurun G, Tio R . Myeloperoxidase polymorphism related to cardiovascular events in coronary artery disease. Am J Med. 2004; 116(6):429-30. DOI: 10.1016/j.amjmed.2003.10.025. View

17.

Klebanoff S . Myeloperoxidase: friend and foe. J Leukoc Biol. 2005; 77(5):598-625. DOI: 10.1189/jlb.1204697. View

18.

Zeka K, Ruparelia K, Arroo R, Budriesi R, Micucci M . Flavonoids and Their Metabolites: Prevention in Cardiovascular Diseases and Diabetes. Diseases. 2020; 5(3). PMC: 5622335. DOI: 10.3390/diseases5030019. View

19.

Steffen Y, Schewe T, Sies H . Myeloperoxidase-mediated LDL oxidation and endothelial cell toxicity of oxidized LDL: attenuation by (-)-epicatechin. Free Radic Res. 2006; 40(10):1076-85. DOI: 10.1080/10715760600883247. View

20.

Vanichkitrungruang S, Chuang C, Hawkins C, Hammer A, Hoefler G, Malle E . Oxidation of human plasma fibronectin by inflammatory oxidants perturbs endothelial cell function. Free Radic Biol Med. 2019; 136:118-134. DOI: 10.1016/j.freeradbiomed.2019.04.003. View